Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atirmociclib plus giredestrant in ER+/HER2- early breast cancer
NCT07890597Phase 3Not yet recruiting
- Sponsor
- Pfizer
- Start
- Dec 2026
- Primary completion
- Apr 2032
01
Overview
A Phase 3 trial of atirmociclib in breast cancer, sponsored by Pfizer. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
atirmociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT07890597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07890597.